![](https://d3ilqtpdwi981i.cloudfront.net/-KYDkLQeMr00ep71jJ0CZY5OSxU=/0x38:371x518/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/24/cd/5a/24cd5aa1-2075-4e5d-a499-737be8ad9cac/BHSF%20Pineapple%20Logo%20%28Imported%20Works%29.png)
Presentation
Assessment of the Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab (PEM).
Journal of Clinical Oncology
(2019)
Disciplines
Publication Date
May 20, 2019
DOI
10.1200/jco.2019.37.15_suppl.2555
Citation Information
Miguel Angel Villalona-Calero, John Paul Diaz, Zuanel Diaz, Wenrui Duan, et al.. "Assessment of the Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab (PEM)." Journal of Clinical Oncology Vol. 37 (2019) p. 2555 - 2555 Available at: http://works.bepress.com/federico-albrecht/14/